Literature DB >> 10894869

Time-dependent relevance of steroid receptors in breast cancer.

D Coradini1, M G Daidone, P Boracchi, E Biganzoli, S Oriana, G Bresciani, C Pellizzaro, G Tomasic, G Di Fronzo, E Marubini.   

Abstract

PURPOSE: To analyze the time-dependent prognostic role of the investigated variables, considered, when appropriate, on a continuous scale, for the purpose of evaluating and describing the interrelationships between clinically relevant patient and tumor characteristics (age, size and histology, and estrogen receptor [ER] and progesterone receptor content) and the risk of new disease manifestation. PATIENTS AND METHODS: We applied a flexible statistical model to a case series of 1,793 patients with axillary lymph node-negative breast cancer with a minimal potential follow-up of 10 years. To avoid a potential confounding effect of adjuvant treatment, only patients given local-regional therapy until relapse were considered.
RESULTS: ER content and tumor size (adjusted for all the other covariates) showed a time-dependent relationship with the risk of new disease manifestations. In particular, ER content failed to show a prognostic effect within the first years of follow-up; thereafter, a positive association with risk of relapse was observed. For tumor size, within the first years of follow-up, the risk of relapse was directly related to size for only tumors up to 2.5 cm in diameter; thereafter, the impact on prognosis progressively decreased.
CONCLUSION: The availability of a long follow-up on a large breast cancer series, as well as the use of innovative statistical approaches, allowed us to explore the functional relation between steroid receptors and clinical outcome and to generate a hypothesis on the involvement of ER in favoring long-term metastasis development.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10894869     DOI: 10.1200/JCO.2000.18.14.2702

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  7 in total

1.  Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration.

Authors:  Douglas G Altman; Lisa M McShane; Willi Sauerbrei; Sheila E Taube
Journal:  BMC Med       Date:  2012-05-29       Impact factor: 8.775

2.  Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration.

Authors:  Douglas G Altman; Lisa M McShane; Willi Sauerbrei; Sheila E Taube
Journal:  PLoS Med       Date:  2012-05-29       Impact factor: 11.069

3.  Modeling the effect of tumor size in early breast cancer.

Authors:  Claire Verschraegen; Vincent Vinh-Hung; Gábor Cserni; Richard Gordon; Melanie E Royce; Georges Vlastos; Patricia Tai; Guy Storme
Journal:  Ann Surg       Date:  2005-02       Impact factor: 12.969

4.  Trefoil factor 1 in early breast carcinoma: a potential indicator of clinical outcome during the first 3 years of follow-up.

Authors:  Milan Markićević; Radan Džodić; Marko Buta; Ksenija Kanjer; Vesna Mandušić; Zora Nešković-Konstantinović; Dragica Nikolić-Vukosavljević
Journal:  Int J Med Sci       Date:  2014-05-01       Impact factor: 3.738

5.  Time-dependent and nonlinear effects of prognostic factors in nonmetastatic colorectal cancer.

Authors:  Sheng-Qiang Chi; Yu Tian; Jun Li; Dan-Yang Tong; Xiang-Xing Kong; Graeme Poston; Ke-Feng Ding; Jing-Song Li
Journal:  Cancer Med       Date:  2017-07-14       Impact factor: 4.452

6.  Vascular endothelial growth factor in node-positive breast cancer patients treated with adjuvant tamoxifen.

Authors:  D Coradini; E Biganzoli; C Pellizzaro; S Veneroni; S Oriana; F Ambrogi; R Erdas; P Boracchi; M G Daidone; E Marubini
Journal:  Br J Cancer       Date:  2003-07-21       Impact factor: 7.640

7.  Comparative benefit from small tumour size and adjuvant chemotherapy: clues for explaining breast cancer mortality decline.

Authors:  Romano Demicheli; Federico Ambrogi
Journal:  BMC Cancer       Date:  2014-09-24       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.